Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Medigene AG < Previous 1 2 Next > Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing October 23, 2023 From Medigene AG Via GlobeNewswire Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023 October 16, 2023 From Medigene AG Via GlobeNewswire Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein September 27, 2023 From Medigene AG Via GlobeNewswire Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library September 18, 2023 From Medigene AG Via GlobeNewswire Medigene AG to present at the Baader Investment Conference 2023 September 11, 2023 From Medigene AG Via GlobeNewswire Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 From Medigene AG Via GlobeNewswire Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes August 30, 2023 From Medigene AG Via GlobeNewswire Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types August 23, 2023 From Medigene AG Via GlobeNewswire Medigene AG to present at the 8th CAR-TCR Summit in Boston August 22, 2023 From Medigene AG Via GlobeNewswire Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update August 17, 2023 From Medigene AG Via GlobeNewswire Medigene to participate in the H.C. Wainwright Immune Cell Engager Virtual Conference August 16, 2023 From Medigene AG Via GlobeNewswire Medigene AG to report Second Quarter and Six Months 2023 Financial Results and Corporate Update on August 17, 2023 August 10, 2023 From Medigene AG Via GlobeNewswire Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies June 22, 2023 From Medigene AG Via GlobeNewswire Medigene to Present Data Highlighting the Enhanced Tumor Cell Killing Effects of Adding the PD1-41BB Switch Receptor to Multiple TCR-T Therapies at the Immuno-Oncology Summit Europe June 14, 2023 From Medigene AG Via GlobeNewswire Medigene to Host Virtual R&D Event on TCR-T Therapies for Solid Tumors June 13, 2023 From Medigene AG Via GlobeNewswire Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs June 01, 2023 From Medigene AG Via GlobeNewswire Medigene AG to participate at BIO International in Boston May 30, 2023 From Medigene AG Via GlobeNewswire Medigene AG Expands Patent Portfolio for its End-to-End Platform May 22, 2023 From Medigene AG Via GlobeNewswire Medigene AG to present at upcoming investor conferences May 08, 2023 From Medigene AG Via GlobeNewswire Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens and increases accuracy of safety assessment May 04, 2023 From Medigene AG Via GlobeNewswire Medigene AG reports financial results and business update for Q1 2023 May 03, 2023 From Medigene AG Via GlobeNewswire Medigene expands end-to-end technology platform through worldwide, exclusive license of a CD40L-CD28 Costimulatory Switch Receptor further enhancing potential to treat solid tumors May 02, 2023 From Medigene AG Via GlobeNewswire Medigene AG to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) April 27, 2023 From Medigene AG Via GlobeNewswire Medigene AG presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers April 24, 2023 From Medigene AG Via GlobeNewswire New data presented at AACR Annual Meeting demonstrates significantly enhanced anti-solid tumor effects of T cells co-expressing an optimal affinity TCR targeting NY-ESO-1 and a PD1-41BB co-stimulatory switch receptor (MDG1015) April 18, 2023 From Medigene AG Via GlobeNewswire Medigene AG to present Phase I clinical data for MDG1011 with poster presentation at EBMT 2023 Annual Meeting April 11, 2023 From Medigene AG Via GlobeNewswire Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development April 04, 2023 From Medigene AG Via GlobeNewswire Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs April 03, 2023 From Medigene AG Via GlobeNewswire Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update March 29, 2023 From Medigene AG Via GlobeNewswire Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston March 28, 2023 From Medigene AG Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.